Guardant Health's GAAP loss for 3 months of 2022 was $123.228 million, up 14.8% from $107.358 million in the prior year. Revenue increased 22.2% to $96.099 million from $78.665 million a year earlier.

Guardant Health has received Japanese regulatory approval for the Guardant360® CDx liquid biopsy test. The test is used to profile tumor mutations in patients with advanced solid cancers.

Guardant Health's GAAP loss for 2021 was $384.77 million, up 56.2% from $246.283 million in the prior year. Revenue increased 30.3% to $373.653 million from $286.73 million a year earlier.

Research on Guardant Health's Guardant360 liquid biopsy test has shown that its data can be used to make treatment decisions for patients with manageable metastatic colorectal cancer. Guardant360 can select people for targeted therapy, determine which patients respond to treatment, and identify genetic changes that predict resistance.